THYROID CANCER IN AN ADOLESCENT WITH CRITICAL SYSTEMIC OSTEOPOROSIS

Authors

  • Tovkai О. A. Ukrainian scientific and practical center of endocrine surgery, transplantation of endocrine organs and tissues of MoH of Ukraine, Kyiv
  • Palamarchuk V. О. Ukrainian scientific and practical center of endocrine surgery, transplantation of endocrine organs and tissues of MoH of Ukraine, Kyiv
  • Mazur О. V. Ukrainian scientific and practical center of endocrine surgery, transplantation of endocrine organs and tissues of MoH of Ukraine, Kyiv
  • Voitenko V. V. Ukrainian scientific and practical center of endocrine surgery, transplantation of endocrine organs and tissues of MoH of Ukraine, Kyiv
  • Zelinska N. B. Ukrainian scientific and practical center of endocrine surgery, transplantation of endocrine organs and tissues of MoH of Ukraine, Kyiv
  • Globa E. V. Ukrainian scientific and practical center of endocrine surgery, transplantation of endocrine organs and tissues of MoH of Ukraine, Kyiv

DOI:

https://doi.org/10.21856/j-PEP.2021.1.08

Keywords:

thyroid cancer, surgical treatment, primary hyperparathyroidism, diagnosis

Abstract

Despite the low incidence of thyroid cancer (PCOS) in children, each case of primary hyperparathyroidism should be analyzed in detail for the presence of a malignant process, especially at too high levels of parathyroid hormone (PTH) and calcium ionized (Ca++) blood. in combination with severe symptoms, which are more often manifested in the form of systemic osteoporosis and fractures of the tubular bones, expressed by the formation of stones in the kidneys and gallbladder. Biochemical measures for primary hyperparathyroidism, both in benign and malignant parathyroid tumors, in addition to elevated PTH and hypercalcemia, are: hypophosphatemia, hypercalciuria (although Ca in the urine may be low in combination with vitamin D deficiency). To determine the genetic cause of hyperparathyroidism, it is possible to perform a genetic research using a target multicancer panel (with analysis of more than 80 genes, including MEN genes). In this case, a mutation of MAX c.25G> T (p.Val9Leu) was detected, which was classified as unclearly significant (VUS). Mutations in the MAX gene have been associated with the development of hereditary pheochromocytoma-paraganglioma, but have not been described in patients with isolated primary hyperparathyroidism, confirming the lack of association between the genetic aspect and the existing parathyroid tumor. One of the causes of parathyroid cancer is operative, with the subsequent dynamic supervision and control of indicators of PTH and Ca++ of blood plasma in combination with imaging methods of research. Increase in the level of the last above reference values in the postoperative period, in this case PTH - 152 pg/ml, which is corrected by alfacalcidol or calcitriol both as monotherapy and in combination with cholecalciferol, lack of topical imaging, do not always indicate persistent disease. In such cases, an additional method of diagnosing the possible persistence of the disease may be PET/CT (with 11C-choline), which allows to differentiate the accumulation of the drug in atypical sites of the surgical operation.

References

Bilezikian JP. Primary Hyperparathyroidism. In: Feingold KR, Anawalt B, Boyce A, et al., Endotext, South Dartmouth, 2000, available at: https://www.ncbi.nlm.nih.gov/books/NBK278923

Palamarchuk VA, Tovkaj AA, Vojtenko VV, et al. Klinichna endokrynologija ta endokrynna hirurgija 2019; 1: 7-17. http://doi.org/10.30978/CEES-2019-1-7.

Heath DA. Endocrinol Metab Clin North Am 1989; 18: 631-646.

Mallet E. Horm Res 2008; 69(3): 180-188.

Nicholson KJ, McCoy KL, Witchel SF, et al. Surgery 2016; 160(4): 1008-1016.

Starker LF, Akerström T, Long WD, et al. Horm Cancer 2012; 3(1-2): 44-51.

Thakker RV. J Intern Med 2016; 280(6): 574-583. https://doi.org/10.1111/joim.12523.

Hyperparathyroidism-jaw tumor syndrome, available at: https://ghr.nlm.nih.gov/condition/hyperparathyroidism-jaw-tumor-syndrome#synonyms.

Roizen J, Levine MA. J Chin Med Assoc 2012; 75(9): 425-434. https://doi.org/10.1016/j.jcma.2012.06.012.

Messerer CL, Bugis SP, Baliski C, Wiseman SM. World J Surg Oncol 2006; 4: 10. https://doi.org/10.1186/1477-7819-4-10.

Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, et al. Nat Genet 2011; 43(7): 663-667.

Lumachi F, Basso SMM, Basso U. Anticancer Res 2006; 26: 4803-4808.

Harari A, Waring A, Fernandez-Ranvier G, et al. J Clin Endocrinol Metab 2011; 96(12): 3679-3686. https://doi.org/10.1210/jc.2011-1571.

Lee PK, Jarosek SL, Virnig BA, et al. Cancer 2007; 109(9): 1736-1741. https://doi.org/10.1002/cncr.22599.

Sadler C, Gow KW, Beierle EA, et al. Surgery 2014; 156(6): 1622-1629. https://doi.org/10.1016/j.surg.2014.08.069.

Sharretts JM, Kebebew E, Simonds WF. Semin Oncol 2010; 37(6): 580-590. https://doi.org/10.1053/j.seminoncol.2010.10.013.

Fernandez-Ranvier GG, et al. Cancer 2009; 115(2): 334-344. https://doi.org/10.1002/cncr.24037.

Carole Guerin, Pauline Romanet, David Taieb, et al. Endocr Relat Cancer 2018; 25(2): T15-T28. https://doi.org/10.1530/ERC-17-0266.

Downloads

Published

2021-03-03

How to Cite

Товкай, О. А., Паламарчук, В. О., Мазур, О. В., Войтенко, В. В., Зелінська, Н. Б., & Глоба, Є. В. (2021). THYROID CANCER IN AN ADOLESCENT WITH CRITICAL SYSTEMIC OSTEOPOROSIS. Problems of Endocrine Pathology, 75(1), 58-65. https://doi.org/10.21856/j-PEP.2021.1.08

Issue

Section

CLINICAL ENDOCRINOLOGY